Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Jan;90(1):82-90.
doi: 10.1016/j.jaad.2023.08.097. Epub 2023 Sep 20.

Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry

Bruce Strober  1 , Laura Ferris  2 , Kristina Callis Duffin  3 , Jud C Janak  4 , Adam P Sima  4 , Thomas Eckmann  4 , Manish Patel  5 , Huzefa Photowala  5 , Vishvas Garg  5 , April Armstrong  6
Affiliations
Free article
Observational Study

Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry

Bruce Strober et al. J Am Acad Dermatol. 2024 Jan.
Free article

Abstract

Background: Psoriasis, an inflammatory skin disease, is often treated with biologic therapeutics.

Objective: To determine the real-world treatment effectiveness of risankizumab, an interleukin-23 inhibitor, in the treatment of moderate-to-severe plaque psoriasis.

Methods: A retrospective, observational study was conducted using the CorEvitas Psoriasis Registry for eligible adults with a diagnosis of moderate-to-severe psoriasis and persistent use of risankizumab at 12 (±3) months after initiation. Skin clearance measures and patient-reported outcomes were analyzed for the entire study population and by prior biologic treatment.

Results: Among 287 patients with persistent risankizumab use at 1 year, most achieved clear or clear/almost clear skin and reported significant reductions in Dermatology Life Quality Index scores, psoriasis symptoms (fatigue, skin pain, and overall itch), and work and activity impairment.

Limitations: The CorEvitas Psoriasis Registry is not necessarily representative of all adults with psoriasis in the United States and Canada and does not measure patient adherence.

Conclusion: Patients treated with risankizumab, regardless of prior treatment, achieved high levels of clear and clear/almost clear skin, Dermatology Life Quality Index scores of 0/1, and significant reductions in psoriasis symptoms (fatigue, skin pain, and overall itch) and work and activity impairment 1 year after initiation.

Keywords: CorEvitas; efficacy; quality of life; real world; risankizumab; treatment targets.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest Dr Strober has served as a consultant (received honoraria) for AbbVie, Almirall, Amgen, Arcutis, Arena, Aristea, Asana, Boehringer Ingelheim, Immunic Therapeutics, Bristol Myers Squibb, Connect Biopharma, Dermavant, EPI Health, Evelo Biosciences, Janssen, Leo, Eli Lilly, Maruho, Meiji Seika Pharma, Mindera Health, Novartis, Ono, Pfizer, UCB Pharma, Sun Pharma, Regeneron, Sanofi-Genzyme, Union Therapeutics, Ventyxbio, and vTv Therapeutics, has stock options with Connect Biopharma and Mindera Health, has served as a speaker for AbbVie, Eli Lilly, Incyte, Janssen, Regeneron, and Sanofi-Genzyme, is a scientific codirector for CorEvitas (formerly Corrona) Psoriasis Registry, has served as an investigator for Dermavant, AbbVie, CorEvitas Psoriasis Registry, Dermira, Cara, and Novartis, and received honorarium for serving as the Editor-In-Chief of the Journal of Psoriasis and Psoriatic Arthritis. Dr Ferris has served as a consultant and is/was an investigator for AbbVie, Amgen, Arcutis, BMS, Dermavant, Janssen, Lilly, Novartis, UCB, Sun Pharma, Boehringer Ingelheim, Ortho, and Pfizer. Dr Duffin is an investigator for, receives research grants from, and/or serves as a consultant or adviser for AbbVie, Amgen/Celgene, Bristol Myers Squibb, Boehringer Ingelheim, CorEvitas, Janssen, Lilly, Novartis, LEO, UCB, and Pfizer. Drs Janak and Sima and Author Eckmann are employees of CorEvitas, LLC (formerly Corrona, LLC). CorEvitas is supported through contracted subscriptions with multiple pharmaceutical companies. This study was a collaborative effort between CorEvitas and AbbVie with financial support provided by AbbVie. Drs Patel, Photowala, and Garg are full-time salaried employees of AbbVie and may own stock/options. Dr Armstrong reported receiving grants and personal fees from AbbVie, Eli Lilly, Leo Pharma, and Novartis Pharmaceuticals Corp, personal fees from Boehringer Ingelheim/Parexel, Bristol Myers Squibb, Celgene, Dermavant, Janssen Pharmaceuticals Inc, Merck, Modernizing Medicine, Ortho Dermatologics, Pfizer Inc, Regeneron Pharmaceuticals, Sanofi-Genzyme, Science 37 Inc, Genentech, GlaxoSmithKline, and Valeant, and grants from Dermira, Janssen Ortho Inc, Kyowa Hakko Kirin, and UCB Pharma outside the submitted work.

Publication types